Trevi Therapeutics
TRVI
137 hedge funds and large institutions have $554M invested in Trevi Therapeutics in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 14 closing their positions.
700% more funds holding in top 10
Funds holding in top 10: 1 → 8 (+7)
381% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $2.23M
193% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 14
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
68% more capital invested
Capital invested by funds: $330M → $554M (+$225M)
25% more funds holding
Funds holding: 110 → 137 (+27)
2.2% more ownership
Funds ownership: 88.95% → 91.16% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$15.8M |
| 2 |
AC
Armistice Capital
New York
|
+$14.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.39M |
| 5 |
BlackRock
New York
|
+$6.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.83M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.5M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.26M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.88M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$5.59M |
TRVI Hedge Fund Activity: Q1 2025 in Review
137 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2025, worth a combined $554M — up 68% from $330M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TRVI positions and 14 closed out — a net gain of 27 holders — while 54 added to existing stakes and 32 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $15.8M. The largest seller was Adage Capital Partners, cutting an estimated $9.83M.
- 137 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2025, up from 110 in Q4 2024.
- Funds reported $554M of Trevi Therapeutics stock for Q1 2025, up 68% quarter-over-quarter.
- 41 funds opened new Trevi Therapeutics positions in Q1 2025 and 14 closed out, a net change of +27 holders.
- The largest Trevi Therapeutics buyer in Q1 2025 was Octagon Capital Advisors, an estimated $15.8M added.
- The largest Trevi Therapeutics seller in Q1 2025 was Adage Capital Partners, an estimated $9.83M sold.
Based on aggregated 13F filings for Q1 2025.